Loading cancer entity…
Loading cancer entity…
Clinical trials
175 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04863339 | Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery | withdrawn | Phase 2 | 0 | University of North Carolina, Chapel HillOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT01203618 | Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas | withdrawn | Phase 2 | 0 | MorphotekINDUSTRY | 1 | Nov 4, 2013 | clinicaltrials |
| Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy |
| withdrawn |
| Phase 2 |
| 0 |
| Burzynski Research InstituteOTHER |
| 1 |
| Jul 10, 2013 |
| clinicaltrials |
Data updated 22 days agoSource updated Apr 5, 2022source: clinicaltrials